Chong Kun Dang said Monday it has launched Cantabell A, a three-agent combination treatment for hypertension and dyslipidemia.

It is the first combination therapy in Korea to combine the high blood pressure drug angiotensin II receptor blocker (ARB) candesartan, calcium channel blocker (CCB) amlodipine, and dyslipidemia treatment atorvastatin.

Chong Kun Dang received approval after proving the safety and efficacy of Cantabell A in treating dyslipidemia and hypertension in phase 3 clinical trial at 17 domestic institutions from April 2018 to July 2019.

The company divided the 154 hypertensive patients with dyslipidemia into three groups. It administered Cantabell A, a combination of candesartan and amlodipine, or a combination of candesartan and atorvastatin, for eight weeks.

Compared to the control group, Cantabell A showed a statistically significant drop in low-density lipoprotein cholesterol (LDL-C) level and improved changes in mean sitting systolic blood pressure (MSSBP).

“Cantabell A is the first combination drug introduced in Korea, offering a new treatment option for dyslipidemia patients with hypertension,” a company official said. “Korea lacks a combination drug based on atorvastatin, so we expect the drug to increase the compliance of hypertension patients.”